Photocure gets patents in Europe, Russia for acne therapy
PHCUF | Quote | Chart | News | PowerRating -- 27 November 2009 - Norwegian pharmaceutical company Photocure ASA (OSL:
PHO) said Thursday afternoon that the European Patent Office and the
Patent Office in Russia granted a patent on its application, tagged
"PDT Acne".
The awarded patents will provide protection for the use of the
5-ALA-ester methyl aminolevulinate -- MAL being the active ingredient
in Photocure's lead dermatology product Visonac -- and other
5-ALA-esters in the treatment of acne until November 2025.
Visonac is a photodynamic therapy (PDT) combining the Visonac cream
with illumination by a red light source to treat acne. The procedure
kills bacteria and appears to have a beneficial effect on sebaceous
glands and inflammatory cells.
Comments on this story may be sent to
nbr.feedback@nordicbusinessreport.com
For full details on (PHCUF) PHCUF. (PHCUF) has Short Term PowerRatings at TradingMarkets. Details on (PHCUF) Short Term PowerRatings is available at This Link.
- Photocure ASA - Notification of trade - 01/29/10
- Photocure ASA - Notification of trade - 01/28/10
- Photocure ASA - Notification of trade - 01/27/10
- Photocure ASA - Notification of trade - 01/26/10
- Photocure ASA - Notification of trade - 01/25/10
- More News >>


